Bellingham Clinicians Sound Alarm as 7-OH Addiction Cases Surge at Pacific Northwest Clinics

Why it matters

On-the-ground clinical reports from Bellingham, Washington reveal that 7-OH addiction is arriving at emergency rooms and treatment clinics faster than practitioners can manage. Real-world treatment data from the Pacific Northwest illustrates the human toll of products sold legally at gas stations and smoke shops without age restrictions.

The big picture

Whatcom County sits in Washington state, where kratom is legal but loosely regulated. Clinicians there describe a sudden increase in patients presenting with dependence on 7-OH products that were, until this week, sold openly alongside energy drinks. The pattern mirrors what poison control centers have tracked nationally: kratom-related exposure calls rising sharply year over year. Local clinical experience gives texture to the national numbers.

Key findings

• Bellingham-area clinicians report seeing approximately four new kratom or 7-OH addiction cases per week
• 7-OH and kratom products are sold in Whatcom County gas stations and smoke shops, often with no age verification
• Products range from a few dollars to hundreds of dollars and are marketed as natural energy boosters and pain relievers
• Clinic staff describe patients presenting with classic opioid withdrawal symptoms after stopping 7-OH use
• Washington state lawmakers have been briefed by local clinicians and are tracking legislative options
• The DEA's August 5 scheduling will affect product availability but does not immediately address withdrawal care for existing users

What they say

Clinicians in Bellingham describe the situation as comparable to walking into a gas station and purchasing a product that acts on the same opioid receptors as fentanyl, legally and without age restriction — a reality practitioners say has created a new category of patient they were not prepared to treat.

Bottom line

Clinicians in the Pacific Northwest are treating a new wave of 7-OH addiction patients weekly, and the DEA's August 5 scheduling does nothing to address withdrawal care for the users already dependent on these products.